NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Clinical trials for NON-MUSCLE INVASIVE BLADDER NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new NON-MUSCLE INVASIVE BLADDER NEOPLASMS trials appear
Sign up with your email to follow new studies for NON-MUSCLE INVASIVE BLADDER NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection targets bladder tumors in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called belzupacap sarotalocan (AU-011) for people with a type of bladder cancer that hasn't spread into the muscle layer. The drug is injected directly into the tumor, sometimes with a laser, to see if it's safe and possible to do. Abo…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE1 • Sponsor: Aura Biosciences • Aim: Disease control
Last updated May 21, 2026 05:26 UTC
-
Bladder cancer drug delivered straight to the source shows promise in early trial
Disease control Recruiting nowThis study tests a new way to treat bladder cancer by placing a drug-releasing system (TAR-210) directly into the bladder. It is for people with non-muscle-invasive or muscle-invasive bladder cancer, especially those with certain genetic changes. The goal is to find the best dose…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
New targeted therapy aims to keep bladder cancer from returning
Disease control Recruiting nowThis study tests a new treatment called TAR-210 (a drug placed directly into the bladder) against standard chemotherapy for people with a high-risk type of bladder cancer that has certain genetic changes (FGFR alterations). Participants have already received BCG therapy. The goal…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New bladder cancer treatment TAR-200 tested in Real-World study
Disease control Recruiting nowThis study follows 150 people with early-stage bladder cancer (NMIBC) who are receiving TAR-200 treatment in everyday medical practice. Researchers want to see how long it takes for the cancer to come back or get worse after starting TAR-200. The goal is to understand how well th…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
New combo therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study tests whether adding the experimental drug V940 to standard BCG immunotherapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning or spreading. About 308 adults whose bladder cancer has not invaded the muscle will b…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
New targeted therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study compares a new drug delivery system (TAR-210) to standard chemotherapy for people with a specific type of bladder cancer that hasn't invaded muscle. The treatment is placed directly into the bladder. About 641 participants will be randomly assigned to receive either TA…
Matched conditions: NON-MUSCLE INVASIVE BLADDER NEOPLASMS
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 01, 2026 15:58 UTC